ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,177Medicare Part D Prescriptions Filled, Including Refills

Rank: 371 out of 1844

$457K Total Retail Price of All Prescriptions

Rank: 431 out of 1844

240 Patients Receiving at Least One Drug in Part D
95%Patients 65 Years and Older
85% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Indiana
Lower avg

Schedule Two
Controlled Substances

10% of this provider’s 240 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

31% of this provider’s 240 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

0% of this provider’s 7,959 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$56 was the average price of a prescription from this provider, compared to $60 among peers.

Prescriptions per Patient

34 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Indiana
LEVOTHYROXINE SODIUM 415 402 1 1
DONEPEZIL HCL 338 334 2 26
FUROSEMIDE 282 270 3 7
HYDROCODONE-ACETAMINOPHEN 274 272 S3 4 2
LISINOPRIL 273 253 5 4
METOPROLOL TARTRATE 220 215 6 11
CITALOPRAM HBR 206 205 7 19
CYMBALTA 194 194 8 36
NAMENDA 190 190 9 33
QUETIAPINE FUMARATE 176 163 10 82
AMLODIPINE BESYLATE 166 166 11 6
OMEPRAZOLE 163 162 12 5
DIVALPROEX SODIUM 144 144 13 74
TRAMADOL HCL 137 137 14 18
WARFARIN SODIUM 125 123 15 13
MIRTAZAPINE 118 115 16 49
LANTUS 117 116 17 42
POTASSIUM CHLORIDE 112 111 18 16
TRAZODONE HCL 103 90 19 43
METOPROLOL SUCCINATE 97 97 20 14
ATENOLOL 96 92 21 17
POLYETHYLENE GLYCOL 3350 90 90 22 39
RISPERIDONE 90 90 22 65
ISOSORBIDE MONONITRATE ER 88 88 24 59
SERTRALINE HCL 82 78 25 21
ALENDRONATE SODIUM 74 74 26 25
NOVOLOG 73 73 27 84
CARVEDILOL 73 73 27 22
KLOR-CON M20 70 70 29 54
OLANZAPINE 68 68 30 117
AVELOX 67 67 31 346
NYSTATIN 65 64 32 85
GLIPIZIDE 64 64 33 70
PRENATABS RX 64 56 33 232
RANITIDINE HCL 63 63 35 38
LOSARTAN POTASSIUM 62 62 36 24
CEPHALEXIN 61 61 37 56
BETAMETHASONE VALERATE 60 60 38 334
ALBUTEROL SULFATE 57 57 39 115
CARBIDOPA-LEVODOPA 57 53 39 86
PANTOPRAZOLE SODIUM 57 57 39 32
FENTANYL 57 57 S2 39 66
SEROQUEL 56 50 43 191
ALLOPURINOL 55 55 44 29
SULFAMETHOXAZOLE-TRIMETHOPRIM 54 54 45 73
EXELON 53 53 46 112
PREDNISONE 50 50 47 40
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 23, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.